Navigation Links
Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug

Pfizer Inc announced an agreement with Schwarz Pharma AG under which it would be acquiring exclusive worldwide rights to fesoterodine, a new drug that can be a treatment option for an overactive bladder. //

"Overactive bladder is a debilitating condition that affects up to 100 million people around the world," said Karen Katen, vice chairman of Pfizer Inc and president, Pfizer Human Health. "We are excited about the potential of this new medicine to offer patients and their doctors a new alternative to existing therapies for managing the symptoms of overactive bladder." Schwarz had submitted an application for fesoterodine approval to both the US Food and Drug Administration and the European Medicines Evaluation Agency (EMEA) earlier this year. Initially Pfizer will pay $100 million to Schwarz Pharma. This amount can be increased provided the drug meets certain milestones. Royalties of both fesoterodine and Pfizer's Detrol product line for treatment of overactive bladder will be paid to Schwarz. Pfizer's Detrol LA is a leading drug that helps control involuntary bladder contractions and decreases the symptoms of urgency with or without frequency and incontinence. Since its introduction it has been prescribed to over 11 million patients worldwide.
'"/>




Page: 1

Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Commences Its Advertising for Celebrex with All the Warnings
8. FDA Approves Pfizer’s Anti-smoking Dru
9. Pfizer vouches safety of long-term inhaled insulin.
10. NICE Setback Rules for Pfizers Inhaled Insulin
11. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
Post Your Comments:
(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...ressed and belong to lower socioeconomic status ha... irrespective of the formula for success//. As per...ncreased level is irrespective of race, age, sex o...ith poverty, per se,’ said lead author Sheldon Coh...
...f the gastrointestinal tract such as gastric bypas... obesity and gastroesophageal reflux// disease res...y presented at the Digestive Disease Week, which r...d physicians from different medical fields such as...
...nearly 15 million Americans suffer Urinary inconti...elief. According to a recent finding//, medical sp...nce in most of the patients with injections made f...After this treatment, the researchers have confirm...
...search into child cancer survivors has revealed th...he chances are twice as much compared// to those w...ypes of cancer survivors, those that have survived...s system tumors run a risk five times more pronoun...
Other Medicine News:Health News:Hormone Levels Increase Due To Socioeconomic Stress 2Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 2Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 3
(Date:7/23/2008)... Systemic Therapy to Treat the Disease -, WAYNE, ...irstCall/ --,Bayer HealthCare Pharmaceuticals and ...nounced that The New England Journal of Medicine p...that Nexavar(R) (sorafenib),tablets decreased the ...ith,unresectable hepatocellular carcinoma (HCC), o...
(Date:7/23/2008)...wire-USNewswire/ -- The following was,released by ..., Ranking Member Smith, and Members of the Committ...., Since I appeared before this Committee almost ...ed with the talented and dedicated professionals,a..., and I have come to,appreciate that much more dee...
(Date:7/23/2008)...ewswire/ -- InCode BioPharmaceutics, Inc.,an emer...eclinical test,results demonstrating the utility o...t of the rare chronic blood disorder paroxysmal no... will be presented at the XXII,International Compl...,2008., The only treatment currently available f...
(Date:7/22/2008)...2 /- Following a,thorough r...Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: ... PI-88 phase 3 study in liver cancer. Progen confi...ng portfolio of compounds and,the company will act...ortunities through Merger & Acquisition activity.,...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Diabetes in the Bedroom 3A Scarier than Halloween 3F 2844 1Diabetes in the Bedroom 3A Scarier than Halloween 3F 2844 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 4Prime Therapeutics Announces URAC Accreditation 2840 1Prime Therapeutics Announces URAC Accreditation 2840 2GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 1GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 2GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 3GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 4GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 5
Horizontal Mini Gel Kit. Gel Bed dimensions: 7.5cm(w) x 10cm(l). Includes one comb and tapered baffles for casting in the unit. Gel bed is UV transparent. Available in clear, blue, yellow, pink,
... gels offer many advantages for nucleic acid separ...cular biologist. Agarose gels are easy to cast and...nderlaying and prevent electrical field discontinu...Horizontal systems are more economical and easier ...
The Mini-Sub cell GT system, with 7 x 10 cm tray, is used for submerged horizontal gel electrophoresis of nucleic acids in mini format 7 x 10 cm agarose gels. The system includes an electrophoresis c
Wide Mini ReadySub-Cell GT Cell, includes buffer tank, lid and electrodes, leveling bubble; accommodates 20-well, 32-well, and 2 x 32-well wide mini ReadyAgarose gels
Medicine Products: